Clinical trial
A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
NCT02020226 is registered in ClinicalTrials.gov with Threshold Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors
- Lead sponsor
- Threshold Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- November 30, 2013
- Completion date
- December 31, 2016
- Enrollment
- 40 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
solid tumors